Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Dehydroequol; NV 06; Phenoxodiol; PXD

Latest Information Update: 24 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novogen
  • Developer MEI Pharma
  • Class Anti-infectives; Anti-inflammatories; Antineoplastics; Antivirals; Hormones; Isoflavones; Small molecules
  • Mechanism of Action Caspase stimulants; NADH oxidase inhibitors; Proto oncogene protein c-akt inhibitors; X-linked inhibitor of apoptosis protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune disorders; Benign prostatic hyperplasia; Fallopian tube cancer; Leukaemia; Ovarian cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Renal cancer; Skin cancer; Transplant rejection

Most Recent Events

  • 28 Jun 2012 Marshall Edwards is now called MEI Pharma
  • 01 Feb 2012 Marshall Edwards completes the OVATURE phase III trial in Ovarian cancer in the USA (NCT00382811)
  • 21 Mar 2011 Efficacy data from a phase II trial in Ovarian cancer (Combination therapy with cisplatin) released by Marshall Edwards
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top